Alexion Pharmaceuticals, Inc. (ALXN)
Q2 2012 Earnings Call
July 25, 2012 10:00 AM ET
Lenny Bell – CEO
Tom Dubin – SVP and Chief Legal Officer
Vikas Sinha – SVP and CFO
David Hallal – SVP, Global Commercial Operations
Steve Squinto – EVP and Head of Research and Development
Geoff Meacham – JP Morgan
Rachel McMinn – Bank of America/Merrill Lynch
Eric Schmidt – Cowen & Company
David Friedman – Morgan Stanley
Shane – Wells Fargo
Salveen Richter – Canaccord
Geoffrey Porges – Bernstein
Navdeep Singh – Deutsche Bank
Ying Huang – Barclays
Ian Somaiya – Piper Jaffray
Matt Roden – UBS
Howard Liang – Leerink Swann
Chris Raymond – Robert Baird
Good day, ladies and gentlemen, and welcome to the Second Quarter 2012 Alexion Pharmaceuticals Earnings Conference Call.
I would now like to turn the presentation over to your host for today, Dr. Bell. Please proceed, sir.
Thank you, operator, and good morning. Thank you for joining us on today’s call to discuss Alexion’s performance for the second quarter of 2012.
With me on the call this morning are members of Alexion management: Steve Squinto, Executive Vice President and Head of R&D; Vikas Sinha, Senior Vice President and Chief Financial Officer; David Hallal, Senior Vice President, Global Commercial Operations; and Tom Dubin, Senior Vice President and Chief Legal Officer. We also welcome our entire Alexion team working around the world.
Vikas, David and Steve will join me on today’s call to report on our progress in the second quarter, and to provide an update on our outlook for the second half of this year.